[HTML][HTML] Nilotinib vs nilotinib plus pegylated interferon α (Peg-IFN) induction and nilotinib or Peg-IFN maintenance therapy for newly diagnosed BCR-ABL1 positive …

A Hochhaus, A Burchert, S Saussele, GM Baerlocher… - Blood, 2019 - Elsevier
Introduction: The TIGER (CML V)-study*(NCT01657604) is a multicenter, randomized phase
III trial to evaluate efficacy and tolerability of nilotinib (NIL) 2* 300mg/d monotherapy vs NIL …

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic …

A Hochhaus, A Burchert, S Saussele, GM Baerlocher… - 2019 - ashpublications.org
Introduction: The TIGER (CML V)-study*(NCT01657604) is a multicenter, randomized phase
III trial to evaluate efficacy and tolerability of nilotinib (NIL) 2* 300mg/d monotherapy vs NIL …

[HTML][HTML] Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive …

A Hochhaus, A Burchert, S Saussele, GM Baerlocher… - Blood - sonar.ch
Methods: In August 2012, recruitment started with a pilot phase, aiming to validate the
recommended dose of Peg-IFN. 25 pilot phase patients were treated with the combination of …

[HTML][HTML] Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive …

A Hochhaus, A Burchert, S Saussele, GM Baerlocher… - Blood - folia.unifr.ch
Methods: In August 2012, recruitment started with a pilot phase, aiming to validate the
recommended dose of Peg-IFN. 25 pilot phase patients were treated with the combination of …